"Transcriptomic Clock: Advancing Neurodegeneration Research"

In a groundbreaking study published on August 4, 2025, researchers have introduced a novel metrics system known as the transcriptomic clock, aimed at identifying potential rejuvenating medications for age-related neurodegeneration. This clock is rooted in analyzing the expression levels of specific genes that fluctuate with the aging process.

Understanding the Transcriptomic Clock

The transcriptomic clock focuses on measuring the degree to which genes are expressed as RNA, which presents a changing profile throughout an individual's life. Researchers utilize this system to identify possible interventions that may rejuvenate the transcriptomic profile, potentially counteracting neurodegenerative effects caused by aging.

Intervention Findings

Initial results indicate that a combination of three selected interventions yielded promising outcomes in animal models, particularly in mice, providing a critical step toward therapeutic applications in humans. Notably, the research draws distinctions between transcriptomics and other methods such as proteomics, which analyze proteins, and epigenetics, which examines DNA methylation profiles. While epigenetics provides a lasting view of biological age, the transcriptomic clock zeros in on functional changes that can be more readily interpreted amidst interventions.

Development of the Clock

The development of this transcriptomic clock required extensive data collection from numerous major databases, including:

• An Alzheimer’s-related database
• A tissue expression project
• Investigations on traumatic brain injuries and dementia
• A brain-specific gene expression study

Ultimately, the analysis encompassed data from 778 unique individuals, all healthy and aged between 20 to 97 years. The research team compiled an impressive collection of 2,458 samples and 43,840 transcriptional profiles from both neuronal progenitor cells (NPCs) and neurons.

Using the expression levels of 365 genes, the clock was calibrated to evaluate how interventions might influence brain aging. Remarkably, despite the lack of an epigenetic basis, the clock was found to be highly effective for estimating chronological age, showcasing an average error of just 2.55 years in validation tests.

Connections to Neuropathology

Further analysis revealed that individuals suffering from neurodegenerative disorders, such as Alzheimer's and Parkinson's, exhibited greater transcriptomic age, a finding supported by significantly low p-values. Additionally, the severity of neurological symptoms positively correlated with aging detected by this clock, thus substantiating the link between transcriptomic deviations and brain aging.

Identifying Rejuvenating Compounds

The researchers meticulously scoured chemical and genetic perturbation datasets, leading to the identification of over 4,000 perturbations that influenced neuronal expression. Among these, 971 items demonstrated rejuvenative potentials in NPCs, while 68 perturbations corresponded to neurons.

Highlighted Compounds

Some of the standout rejuvenators in NPCs include:

• BGT-226 – mTOR inhibitor, previously not approved for cancer treatments.
• WYE-354 – also inhibits mTOR.
• Alvocidib – approved for leukemia.
• Iloprost – a hypertension drug also assessed for age-related benefits.
• BRD-K48950795 – in the experimental stage.

In neurons, various potential cancer drugs were highlighted alongside the already approved ponatinib.

Results from Animal Testing

In subsequent trials, a cocktail of three drugs—a combination of 5-azacytidine, tranylcypromine, and JNK-IN-5A—demonstrated a reduction in anxiety behaviors in 18-month-old mice. Remarkably, the gene expression profile after treatment exhibited similarities to younger cohorts, indicating functional rejuvenation.

Future Perspectives

The research team asserts that extensive human trials are necessary to validate these findings and ascertain the efficacy of these interventions, particularly in translational medicine. This line of inquiry may usher in new therapeutic strategies for mitigating the impacts of aging in the human brain.

Conclusion

The inception of the transcriptomic clock not only holds promise for uncovering drugs that can rejuvenate neural function but also reveals a compelling relationship between gene expression profiles and the aging process. It emphasizes the importance of continuous research and investigation into pharmacological compounds that possess age-reversing capabilities.

Funding Statement

The research was funded through various grants, and the authors emphasize that their non-profit foundation remains committed to advancing knowledge without ulterior commercial motives.

References

[1] Nelson, P. T., et al. (2011). Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta neuropathologica, 121(5), 571-587.

[2] Podtelezhnikov, A. A., et al. (2011). Molecular insights into the pathogenesis of Alzheimer’s disease and its relationship to normal aging. PloS one, 6(12), e29610.

[3] Shen, Y. R., et al. (2024). Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming. Cell Stem Cell, 31(12), 1741-1759.

[4] Plesa, A. M., et al. (2023). Transcriptomic reprogramming screen identifies SRSF1 as rejuvenation factor. bioRxiv, 2023-11.